Our portfolio
KDventure’s portfolio consists of life science companies with the potential to address significant medical needs and create long-term value. Here you get an overview of the companies’ projects, development phases and upcoming key milestones.
Our portfolio and its development
The portfolio companies develop highly differentiated and commercially attractive products with the potential to deliver both compelling clinical and health-economic benefits, as well as attractive returns. Here you can see an overview of the pharmaceutical and medtech portfolio.
10
Portfolio companies
4
Late-stage clinical projects
5
Target year 2026
Dilafor
pharma
Tafoxiparin
Ownership 32%
Initiering av förlossning
Target year 2027
BOOST Pharma
pharma
BT-101
Ownership 14%
Osteogenesis imperfecta
Target year 2029
Umecrine Cognition
pharma
Golexanolone
Ownership 59%
Primary biliary cholangitis
Target year 2026
Parkinson's disease
Target year
Modus Therapeutics
pharma
Sevuparin
Ownership 55%
Sepsis/septisk chock
Target year 2027
Anemi kronisk inflammation/njursjukdom
Target year 2026
Svår malaria
Target year
AnaCardio
pharma
AC01
Ownership 10%
Hjärtsvikt
Target year 2028
PharmNovo
pharma
PN6047
Ownership 5%
Nervsmärta
Target year 2027
SVF Vaccines
pharma
SVF-001
Ownership 33%
Hep. B/D
Target year 2027
Covid-19
Target year
CCHF
Target year 2026
Aprea Therapeutics
pharma
APR-1051 / ATRN-119
Ownership 1%
DDR i onkologi
Target year 2026
Biosergen
pharma
BSG005
Ownership 1%
Promimic
medtech
HAnano Surface
Ownership 12%
Medical implant coatings
Target year
No project matches the search criteria.